Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company headquartered in Coral Gables, Florida. The company employs 112 people and generates approximately $50 million in annual revenue. Catalyst Pharmaceuticals focuses on acquiring, developing, and commercializing innovative medications for patients with rare diseases. Catalyst Pharmaceuticals specializes in developing treatments for rare diseases, with a particular focus on Lambert-Eaton myasthenic syndrome (LEMS). Their flagship product, FIRDAPSE® (amifampridine) Tablets 10 mg, is approved by the U.S. Food & Drug Administration (FDA) for the treatment of adults and children ages six to seventeen with LEMS. FIRDAPSE is also approved for use in Canada for the treatment of adult patients with LEMS. The company is committed to providing cutting-edge, best-in-class medicines for patients with rare diseases. Catalyst Pharmaceuticals prioritizes patient focus and strives to develop a robust pipeline of innovative treatments. For more information about Catalyst Pharmaceuticals Inc., please visit their website at catalystpharma.com.